“I buy on the assumption that they could close the market the next day and not reopen it for five years.”
— Warren Buffett
Gilead Sciences stock generated a strong five-year total return for investors who bought shares in September 2021 and reinvested dividends. Looking at the full return profile of NASD: GILD helps separate business performance from short-term market noise and highlights how price appreciation and dividend income combined over the holding period.
The broader point is straightforward: a stock is ultimately a claim on a business, and a five-year holding period provides a useful window for judging whether the underlying economics improved. In Gilead’s case, the outcome over this span was favorable, with both capital gains and reinvested dividends contributing meaningfully to shareholder returns.
GILD 5-Year Return Details
| Start date: | 09/14/2021 |
|
|||
| End date: | 09/11/2026 | ||||
| Start price/share: | $70.45 | ||||
| End price/share: | $143.72 | ||||
| Starting shares: | 141.94 | ||||
| Ending shares: | 170.25 | ||||
| Dividends reinvested/share: | $15.22 | ||||
| Total return: | 144.69% | ||||
| Average annual return: | 19.62% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $24,467.67 | ||||
A $10,000 investment in Gilead Sciences on 09/14/2021 would have grown to $24,467.67 by 09/11/2026, assuming dividends were reinvested. That equates to a total return of 144.69% and an annualized return of 19.62%. Framed differently, the investment more than doubled over the period, with reinvested income amplifying the effect of the stock’s price increase.
These figures underscore an important distinction in equity analysis: total return is not the same as share price return. Gilead’s stock price rose from $70.45 to $143.72, but the final outcome was enhanced by cash distributions that were reinvested into additional shares. The share count increased from 141.94 to 170.25 over the period, illustrating how dividend reinvestment can compound ownership over time. [These numbers were computed with the Dividend Channel DRIP Returns Calculator.]
What Drove the Total Return
Gilead Sciences’ five-year result came from two sources:
- Share price appreciation: the stock advanced from $70.45 to $143.72.
- Dividend income: investors received $15.22 per share in dividends over the holding period, with those payments assumed to be reinvested.
This combination matters because high-quality return analysis should capture the full economic benefit delivered to shareholders. For dividend-paying pharmaceutical companies, ignoring reinvested distributions can materially understate long-term performance.
Dividend Yield and Yield on Cost
Based on the most recent annualized dividend rate of $3.28 per share, GILD has a current yield of approximately 2.28%. Another useful measure is yield on cost, which compares the current annualized dividend with the original purchase price rather than the current share price.
Using the original entry price of $70.45 per share, Gilead’s current annualized dividend translates into a yield on cost of roughly 4.66%. That figure is higher than the current yield because the dividend is being measured against a lower historical purchase price.
Yield on Cost Explained
Yield on cost answers a simple question: how much annual dividend income is the investor now earning relative to the original capital committed?
- Current annualized dividend: $3.28 per share
- Original purchase price: $70.45 per share
- Yield on cost: about 4.66%
It is a useful retrospective metric, although it does not replace current yield when comparing present-day income opportunities across stocks.
Why the Five-Year Lens Matters
A five-year holding period is often long enough to reveal whether a company’s earnings base, capital allocation, and product portfolio are supporting durable shareholder returns. In the case of Gilead Sciences, the period demonstrates that patient ownership was rewarded. It also shows why entry point matters: buying a cash-generative business at a moderate valuation can improve both upside capture and income efficiency over time.
That said, historical performance is most informative when paired with forward-looking analysis. For Gilead, the next phase of returns will depend less on what the stock did since 2021 and more on factors such as revenue durability across core therapies, the strength of its pipeline, margin resilience, and management’s capital allocation decisions.
“While some might mistakenly consider value investing a mechanical tool for identifying bargains, it is actually a comprehensive investment philosophy that emphasizes the need to perform in-depth fundamental analysis, pursue long-term investment results, limit risk, and resist crowd psychology.” — Seth Klarman
